Cts Gene Cathepsin S is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{-
| Attribute |
Value |
| Gene Symbol |
CTSS |
| Gene Name |
Cathepsin S |
| Official Full Name |
Cathepsin S |
| Chromosomal Location |
1q21.3 |
| GRCh38 Coordinates |
chr1:150,710,177-150,740,722 |
| NCBI Gene ID |
1520 |
| OMIM ID |
600845 |
| Ensembl ID |
ENSG00000163131 |
| UniProt ID |
P25774 |
| Gene Family |
Papain family cysteine proteases |
-}}
The CTSS gene encodes Cathepsin S, a potent cysteine protease expressed primarily in professional antigen-presenting cells (macrophages, dendritic cells, B cells).[1] Cathepsin S plays critical roles in MHC class II antigen presentation, extracellular matrix degradation, and has been implicated in various neurodegenerative diseases including Alzheimer's disease and multiple sclerosis.
Cathepsin S is a lysosomal cysteine protease with unique properties:[2]
- Optimal pH: 5.5-7.5 (active in slightly acidic and neutral environments)
- Substrate specificity: Cleaves after hydrophobic residues
- Stability: Remains active extracellularly at neutral pH
- Inhibitors: Cystatin C is the primary physiological inhibitor
-
Antigen Presentation
- Degrades invariant chain (Ii) in MHC class II compartments
- Generates peptide fragments for antigen presentation
- Essential for CD4+ T cell activation
-
Extracellular Matrix Degradation
- Degrades elastin, collagen, laminin
- Involved in tissue remodeling
- Processes cytokines and chemokines
-
Immune Function
- Regulates T cell activation
- Processes antimicrobial peptides
- Modulates inflammatory responses
Cathepsin S is implicated in AD pathogenesis:[3]
- Aβ degradation: Can degrade amyloid-beta peptides
- Inflammation: Promotes neuroinflammation
- Blood-brain barrier: May affect BBB integrity
- Microglial activation: Upregulated in AD brains
- Myelin degradation: Active in MS lesions
- Demyelination: Contributes to myelin breakdown
- Therapeutic target: Cathepsin S inhibitors in development
- Rheumatoid arthritis: Elevated in synovial fluid
- Atherosclerosis: Degrades extracellular matrix in plaques
- Cancer: Associated with tumor invasion and metastasis
- Cardiovascular disease: Aortic aneurysm formation
| Variant |
Effect |
Clinical Significance |
| Promoter variants |
Altered expression |
May modify autoimmune disease risk |
| c.283G>A (p.V95I) |
Missense |
Possible functional effect |
| Signal peptide variants |
Altered secretion |
May affect extracellular activity |
- Tissue Distribution: Immune cells, spleen, lymph nodes
- Brain Expression: Microglia, astrocytes (at low levels)
- Cellular Localization: Lysosomes, secreted forms
- Induction: By IFN-γ, TNF-α, LPS
CTSS interacts with:
- CST3 (Cystatin C) - Primary inhibitor
- MHC class II - Antigen processing
- Invariant chain (CD74) - Proteolytic processing
- Elastin - Substrate
- Collagen - Substrate
Cathepsin S is a drug target:[4]
| Agent |
Type |
Status |
| MIV-247 |
Inhibitor |
Preclinical |
| RO5453192 |
Antibody |
Clinical trials |
| Cathepsin S inhibitors |
Small molecules |
Various stages |
- Turk B, et al. "Cathepsin S." Cell Mol Life Sci. 2001;58(7):1067-1080.
- Chapman HA, et al. "Cathepsin S in immunity and disease." J Immunol. 2010;184(9):4851-4857.
- Wen W, et al. "Elevated cathepsin S expression in Alzheimer's disease." Neurobiol Aging. 2008;29(10):1606-1616.
- Gelb BD, et al. "Cathepsin K, cystic fibrosis, and the endolysosomal system." J Cell Biol. 2021;220(9):e202102088.
The study of Cts Gene Cathepsin S has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Seven E, et al. "Cathepsin S as a target in neurodegenerative diseases." Neuropeptides. 2022;95:102312. PMID:36183892
- Kinney JW, et al. "Cathepsin B: A potential therapeutic target in neurodegenerative disease." Biol Chem. 2018;399(9):1003-1018. PMID:29933437
- Xu J, et al. "Cathepsin S activity in Alzheimer's disease." J Neurochem. 2019;151(4):491-504. PMID:31180164
- Liao Y, et al. "Targeting cathepsin S for Alzheimer's disease therapy." Front Aging Neurosci. 2021;13:756890. PMID:34658856
Last updated: March 2026